newsfilter
← Latest News
GlobeNewswire·

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by